KeChow Pharma
A clinical-stage Chinese biotech developing novel, best-in-class small molecule drugs for oncology, with its first NMPA-approved MEK inhibitor for NRAS-mutant melanoma.
Private Company
Funding information not available
AI Company Overview
A clinical-stage Chinese biotech developing novel, best-in-class small molecule drugs for oncology, with its first NMPA-approved MEK inhibitor for NRAS-mutant melanoma.
Technology Platform
Chemistry-driven drug discovery platform focused on designing novel, high-selectivity small molecule compounds with best-in-class potential, primarily targeting kinase pathways.
Opportunities
Risk Factors
Competitive Landscape
Competes in the targeted therapy space for melanoma (e.g., against other MEK inhibitors like trametinib and binimetinib) and broader oncology innovators; differentiates through its focus on novel chemical entities and best-in-class potential for specific Chinese patient populations.